abciximab

abciximab

abciximab

abciximab n.

Abciximab‐induced thrombocytopenia

Ventricular septal rupture following abciximab infusion

Are tirofiban and abciximab identical in efficacy?

Are tirofiban and abciximab identical in efficacy?: reply

Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction

Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14

Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes

Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial

Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 Fab (abciximab): a possible mechanism for influencing restenosis

Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty

Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction

Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting

Abciximab-facilitated percutaneous coronary intervention and long-term survival—a prospective single-center registry

Three-year duration of benefit from abciximab in patient receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study

Three-year duration of benefit from abciximab in patient receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study: reply

One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel†